Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyridoxamine for Autism Spectrum Disorder (ASD) – Exploratory Phase 2 Trial
jRCT2021200001Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of pyridorin in Autism Spectrum Disorder (ASD) (6 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Change in ABC-J excitatory subscale score from baseline. Started Sep 2018; status: completed.
02
Drugs
pyridorin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on jRCT2021200001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021200001.